Sartorius Stedim Biotech S.A.
SDMHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.26 | -1.10 | 0.29 | 4.60 |
| FCF Yield | 2.61% | 1.24% | 0.64% | 0.83% |
| EV / EBITDA | 30.45 | 33.82 | 22.05 | 56.93 |
| Quality | ||||
| ROIC | 4.09% | 5.09% | 19.11% | 18.77% |
| Gross Margin | 43.41% | 44.44% | 52.52% | 53.79% |
| Cash Conversion Ratio | 3.72 | 1.86 | 0.54 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.33% | -1.30% | 22.28% | 26.08% |
| Free Cash Flow Growth | 74.23% | 50.14% | -51.15% | 44.35% |
| Safety | ||||
| Net Debt / EBITDA | 3.27 | 4.72 | 0.77 | 0.50 |
| Interest Coverage | 2.25 | 3.84 | 53.51 | 83.23 |
| Efficiency | ||||
| Inventory Turnover | 2.30 | 1.75 | 1.62 | 1.70 |
| Cash Conversion Cycle | 122.00 | 147.68 | 212.50 | 145.47 |